Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that it has launched its new Unyvero i60 Implant and Tissue Infection (ITI) cartridge in Europe. The new cartridge for the Unyvero system was developed to rapidly identify more than 90 pathogens and more than 20 resistance markers common in eight clinical indications. Commercial launch and roll-out has already begun in close collaboration with Heraeus Medical GmbH, the development and commercialization partner for the Unyvero i60 cartridge. The Company has made first placements at major clinical centers in Germany, Austria and Switzerland (DACH market).